Synthonics
Private Company
Funding information not available
Overview
Synthonics is a private, pre-revenue biotech firm founded in 2018 and headquartered in Blacksburg, Virginia, with a focus on small molecule drug development. The company's core technology involves chelating metal ions to known drug compounds to create novel Metal Coordinated Pharmaceuticals (MCPs) with superior absorption and efficacy profiles. With an initial patent granted in 2010 and a growing IP portfolio, Synthonics has demonstrated proof-of-concept in human studies and has entered into its first licensing agreement. The company operates in the niche but promising field of metallodrugs, seeking to overcome limitations of traditional organic pharmaceuticals.
Technology Platform
Metal Coordinated Pharmaceuticals (MCP) platform that chelates transition metal ions (e.g., zinc) to existing drug molecules to improve their absorption, efficacy, and pharmacokinetic profiles.
Opportunities
Risk Factors
Competitive Landscape
Synthonics competes with other drug reformulation and delivery technology companies (e.g., those using prodrugs, nanoparticles, or crystal engineering). It also operates in the broader metallodrug space, which includes companies developing novel inorganic complexes for oncology and diagnostics. Its unique niche is the specific coordination of metals to approved organic drugs.